cancer inhibitors trang 3 tải miễn phí từ TAILIEUCHUNG

"cancer inhibitors" trang 3 - tải miễn phí từ Tailieuchung

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

14 52 1

Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features

Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features

15 24 1

Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing

Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing

9 44 1

Statin use and association with colorectal cancer survival and risk: Case control study with prescription data linkage

Statin use and association with colorectal cancer survival and risk: Case control study with prescription data linkage

10 34 1

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-smallcell lung cancer patients: A retrospective multicenter study

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-smallcell lung cancer patients: A retrospective multicenter study

11 23 1

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): Protocol of an open-label, singlearm phase II trial

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): Protocol of an open-label, singlearm phase II trial

7 45 1

Báo cáo khoa học: EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors

Báo cáo khoa học: EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors

11 62 0

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

11 65 0

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

11 40 0

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: A metaepidemiological investigation

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: A metaepidemiological investigation

10 60 0

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis

10 42 0

Comparative effectiveness of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: A nationwide high-risk cohort study

Comparative effectiveness of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: A nationwide high-risk cohort study

12 97 1

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

7 48 1

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: A Meta-analysis and systematic review

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: A Meta-analysis and systematic review

9 44 1

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: A systematic review and meta-analysis

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: A systematic review and meta-analysis

9 29 1

Identification of novel class of triazoloThiadiazoles as potent inhibitors of Human heparanase and their anticancer activity

Identification of novel class of triazoloThiadiazoles as potent inhibitors of Human heparanase and their anticancer activity

14 60 1

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

10 56 1

Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity

Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity

12 41 1

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma

4 48 1

Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: A report from population-based Lithuanian haematological disease registry 2000–2013

Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: A report from population-based Lithuanian haematological disease registry 2000–2013

10 24 1

Đầu
1
2
[ 3 ]
4
5
6
7
8
9
10
11
12
13
14
Cuối

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.